MannKind Corporation entered into a Securities Purchase Agreement for a $50 million private placement of common stock and pre-funded warrants. The company will use the proceeds to fund a $45 million contingent value rights payment obligation triggered by the FDA approval of Furoscix ReadyFlow. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases.
